Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 9/20 | 0.36 |
| ▸ | LATS1 | O95835 | 2/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787398 | 0.86 | CYP3A4 (0.38) | CYP3A4CYP11B1CYP11B2DRD2LATS1 | |
| SCHEMBL6794608 | 0.80 | DRD2 (0.35) | CYP3A4CYP11B1CYP11B2DRD2LATS1 | |
| SCHEMBL6793729 | 0.79 | CYP3A4 (0.38) | CYP3A4CYP11B1CYP11B2DRD2LATS1 | |
| SCHEMBL6794500 | 0.78 | CYP11B1 (0.38) | CYP3A4CYP11B1CYP11B2DRD2LATS1 | |
| SCHEMBL3601640 | 0.78 | CYP3A4 (0.38) | CYP3A4CYP11B1CYP11B2DRD2LATS1 | |
| SCHEMBL3602634 | 0.77 | PDPK1 (0.38) | CYP3A4CYP11B1CYP11B2DRD2LATS1 | |
| SCHEMBL6793980 | 0.77 | LATS1 (0.37) | CYP3A4CYP11B1CYP11B2DRD2LATS1 | |
| SCHEMBL6793842 | 0.77 | DRD2 (0.35) | CYP3A4CYP11B1CYP11B2DRD2LATS1 | |
| Hydrochloric Acid SCHEMBL6799428 | 0.76 | PDPK1 (0.36) | TDP1 | |
| SCHEMBL6792392 | 0.73 | CYP11B1 (0.39) | CYP3A4CYP11B1CYP11B2DRD2LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CYP3A4 2152/4885CYP11B1 785/4885CYP11B2 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.